Role of the serum levels of the inter-organs messenger fibroblast growth factor 21 (FGF21) in the diagnosis and prognosis of breast cancer patients

Cell Communication and Signaling, Год журнала: 2025, Номер 23(1)

Опубликована: Янв. 21, 2025

FGF21 regulates local and systemic metabolic homeostasis. High serum was found in obesity, syndrome, type 2 diabetes mellitus, coronary heart disease. The pathways linking obesity breast cancer remain elusive. We aimed to analyze the patients at diagnosis. Circulating levels 45 women (median age 59, range 32–88 years) 51 age-matched healthy controls were evaluated using a quantitative ELISA assay. Patients' samples obtained before surgery ahead of any previous therapy. Breast showed significantly elevated 267.13, 28.41-780.45) respect (76.86, 0.00-425.60) (p < 0.0001). A ROC curve determined cut-off value 130.64 pg/ml define positive or high levels. Based on this point, 30/45 (66.7%) as compared 18/51 (35.3%) controls. could be useful highly sensitive diagnosis biomarker for early detection. did not find significant association between levels, many clinical-pathological parameters primary Interestingly, statistically correlation body mass index (BMI). Furthermore, with had worst overall survival (Log Rank Test [Mantle Cox] p = 0.017). propose promising diagnostic prognosis oncological

Язык: Английский

New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment

Cancers, Год журнала: 2025, Номер 17(2), С. 165 - 165

Опубликована: Янв. 7, 2025

Background/Objectives: Endocrine therapies that comprise anti-estrogens and aromatase inhibitors (AIs) are the standard treatment for estrogen receptor-positive (ER+) (Luminal A) breast cancer-the most prevalent subtype. However, emergence of resistance restricts their success by causing tumor relapse re-growth, which demands a switch towards other therapeutic approaches in order to minimize or overcome resistance. Indeed, this clinical limitation highlights search new molecules improve cancer treatment. Recently, strategies address multiple targets have been emerging, multi-target drugs potential become future anti-cancer molecules. Our group has searching compounds, as part this, our study aims understand three steroidal (AIs): 7α-methylandrost-4-en-17-one (6), 7α-methylandrost-4-ene-3,17-dione (10a) androsta-4,9(11)-diene-3,17-dione (13). Methods: Their vitro actions molecular mechanisms were elucidated sensitive ER+ aromatase-overexpressing cell line, MCF-7aro cells, well an AI-resistant LTEDaro cells. Results: All AIs (10 µM) prevented proliferation cells arresting cycle progression. Interestingly, all act androgen receptor (AR) agonists modulate ER levels, synthesis signaling induce apoptosis Additionally, these also re-sensitize resistant promoting apoptosis, offering benefit. Conclusions: Overall, polypharmacological compounds discovered that, acting AIs, modulators AR agonists, impair growth. is breakthrough on drug discovery it presents with appealing properties action cancer.

Язык: Английский

Cannabinol improves exemestane efficacy in estrogen receptor-positive breast cancer models: a comparative study with cannabidiol

European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177712 - 177712

Опубликована: Май 1, 2025

Язык: Английский